1. Home
  2. HIW vs SUPN Comparison

HIW vs SUPN Comparison

Compare HIW & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIW

Highwoods Properties Inc.

HOLD

Current Price

$29.77

Market Cap

3.2B

Sector

Real Estate

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$46.31

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIW
SUPN
Founded
1978
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.0B
IPO Year
1995
2010

Fundamental Metrics

Financial Performance
Metric
HIW
SUPN
Price
$29.77
$46.31
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$27.57
$61.60
AVG Volume (30 Days)
1.6M
586.2K
Earning Date
04-28-2026
05-05-2026
Dividend Yield
8.43%
N/A
EPS Growth
54.26
N/A
EPS
0.29
N/A
Revenue
$806,112,000.00
$392,755,000.00
Revenue This Year
$6.03
$22.70
Revenue Next Year
$3.58
$19.14
P/E Ratio
$100.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.45
$31.16
52 Week High
$32.76
$59.68

Technical Indicators

Market Signals
Indicator
HIW
SUPN
Relative Strength Index (RSI) 65.43 52.65
Support Level $28.22 $43.43
Resistance Level $30.83 $46.79
Average True Range (ATR) 0.85 1.35
MACD -0.12 0.32
Stochastic Oscillator 58.79 89.83

Price Performance

Historical Comparison
HIW
SUPN

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: